Abstract Small-fiber polyneuropathy (SFPN) causes nonspecific symptoms including chronic pain, cardiovascular, gastrointestinal, and sweating complaints. Diagnosis is made from history and exam in patients with known risk factors such as diabetes, but objective test confirmation is recommended for patients without known risks. If tests confirm SFPN, and it is ''initially idiopathic'' (iiSFPN), screening for occult causes is indicated. This study's aim was to evaluate the 21 widely available, recommended blood tests to identify the most cost-effective ones and to learn about occult causes of iiSFPN. Records were reviewed from all 213 patients with SFPN confirmed by distal-leg skin biopsy, nerve biopsy, or autonomic-function testing in our academic center during 2013. We determined the prevalence of each abnormal blood-test result (ABTR) in the iiSFPN cohort, compared this to population averages, and measured the costs of screening subjects to obtain one ABTR. Participants were 70 % female and aged 43.0 ± 18.6 years. High erythrocyte sedimentation rate (ESR) and antinuclear antibody (ANA; C 1:160 titer) were most common, each present in 28 % of subjects. The ABTR C3 9 more prevalent in iiSFPN than in the total population were high ESR, high ANA, low C3, and Sjögren's and celiac autoantibodies. Together, these suggest the possibility of a specific association between iiSFPN and dysimmunity. ABTR identifying diabetes, prediabetes, and hypertriglyceridemia were less common in iiSFPN than in the population and thus were not associated with iiSFPN here. The six most cost-effective iiSFPN-associated blood tests-ESR, ANA, C3, autoantibodies for Sjögren's and celiac, plus thyroid-stimulating hormone-had estimated cost of $99.57/person and 45.6 % probability of obtaining one abnormal result. Angiotensin-converting enzyme was elevated in 45 %, but no patients had sarcoidosis, so this test was futile here.
Introduction
Distal peripheral polyneuropathy is highly prevalent and often disabling. The most common complaints are sensory. Many of these patients have small-fiber-predominant polyneuropathies (SFPN), in which the unmyelinated C-fibers, A-delta fibers, and/or autonomic axons are exclusively or preferentially damaged. These thin ''small-fibers'' use continuous rather than saltatory conduction, and they have limited axon-transport capacity, so disruptions in energy or nutrient supply damage them preferentially. Small fibers evolved to detect and signal dangerous stimuli (transducing them as ''pain'' and ''itch'') to trigger defensive responses, and to regulate organs and tissues to optimize their function. Because of these multiple tasks, SFPN presents with varying combinations of symptoms. These include widespread chronic pain and/or itch, postural hypotension and tachycardia, nausea, constipation and/or diarrhea, and less often, urological complaints [1, 2] . Neurological examination can be unrevealing in SFPN since muscle bulk, strength, tendon reflexes, and sensations of touch, position, and vibration are usually preserved.
Electromyography and surface nerve-conduction study (EMG/NCS) do not detect small-fiber potentials, and thus they can neither detect nor exclude SFPN. Diagnosing SFPN can be difficult unless typical symptoms arise in patients with well-recognized causes of neuropathy. In such patients, the diagnosis and its cause are inferred from the medical history, the current symptoms, and any exam findings.
In many countries, diabetes is the most common cause of polyneuropathy [3] ; it causes about half of SFPN in US population-based studies [4] . The second largest group of SFPN patients, comprising 20-50 % in recent series [3] [4] [5] [6] [7] , have ''initially idiopathic'' or ''cryptogenic'' SFPN (here abbreviated as iiSFPN). They are the focus of the current study. The reason to try to identify undetected causes in iiSFPN patients is that peripheral axons grow throughout life, so diagnosing polyneuropathy and treating its underlying causes can spur axonal regeneration, which can improve or cure patients' symptoms. In contrast, even effective palliative treatments neither restore axons nor improve their function. They also add costs and risks including opioid abuse. Therefore, neurology organizations recommend that patients with initially idiopathic sensory polyneuropathy be screened for its common occult causes [8] . In a recent study of patients with mixed distal polyneuropathies, screening led to potentially diseasemodifying management changes in 25 % [9] .
Previously, objective confirmation of suspected SFPN required surgical biopsy of a sensory nerve. This is invasive, expensive, and thus only rarely performed. Today, PGP9.5-immunolabeled distal-leg skin biopsies and composite autonomic-function testing (AFT) are also endorsed by neurological societies and performed more widely, identifying increasing numbers of iiSFPN patients who need screening [10] [11] [12] [13] . Research application of skin biopsy and AFT has suggested that SFPN appears to be a common denominator in several ill-defined syndromes that include chronic widespread pain and/or symptoms of dysautonomia. For instance, half among 152 patients with postural orthostatic tachycardia syndrome (POTS) had abnormal small-fiber mediated sweat production, meeting diagnostic criteria for SFPN [14] . In addition, among 41 patients with unexplained chronic widespread pain starting in childhood (i.e., juvenile fibromyalgia), 30 % of skin biopsies, 53 % of AFT, and 2/2 nerve biopsies were diagnostic for SFPN [15] . Multiple groups have now reported that almost half of patients with fibromyalgia have objective evidence of underlying SFPN [16] [17] [18] [19] [20] [21] [22] [23] . Given that fibromyalgia affects 2-5 % of the world's population [24] , idiopathic SFPN may be far more common than appreciated, so cost-effective screening strategies are needed. Plus, analyzing large samples of verified SFPN patients, as performed here, can inform about underlying causes and mechanisms.
Blood tests are the major way of identifying occult causes of polyneuropathy. Sensory and autonomic-predominant polyneuropathies are linked to abnormal bloodtest results for diabetes [3] , alcohol-related liver dysfunction [25] , heavy-metal toxicity [26] , deficiencies of vitamins B12 (cobalamin) and folate [27, 28] , high vitamin B6 [29] , hypothyroidism and hyperthyroidism [30, 31] , paraproteinemia [32] , sarcoidosis [33] , and systemic autoimmune disorders including Sjögren's syndrome (SS) [34, 35] , systemic lupus erythematosus [36] , and celiac [37] [38] [39] . Infectious causes include human immunodeficiency virus [40] , hepatitis C [41] , leprosy [42] , and Lyme disease [43] . Rare genetic variants underlie some familial and sporadic cases, with a Dutch SFPN cohort having 2.3 % prevalence of SCN9A sodium-channel mutations [7] .
Insufficient screening increases the risk of missing potentially curable causes but excess screening is expensive, ineffective, and can lead to more testing, risk, worry, and cost. Thus, the sensitivity, specificity of association, and cost effectiveness of recommended blood tests should be defined to guide decisions about how to screen iiSFPN patients for causality. Table 1 summarizes the sample characteristics and tests evaluated in previous screening studies of sensory-predominant polyneuropathies. The American Academy of Neurology's 2008 systematic review of screening studies only endorsed testing blood glucose, B12 and metabolites, and serum protein electrophoresis/immunofixation (SPEP/IFIX) [8] . However, these recommendations were based on studies with varying inclusion criteria. More relied on EMG/NCS than on skin biopsy, nerve biopsy, or AFT (Table 1) , meaning their conclusions apply more to large-fiber than small-fiber neuropathy. Furthermore, older studies can lose relevance due to recent health trends, including earlier detection of diabetes and prediabetes. Plus, each country and region has different prevalences of specific diseases and different testing customs, so recommendations from one place cannot be globally generalized. The current study has the advantage of having the largest sample of patients with verified SFPN. It is also among the first to compare the prevalences of abnormal bloodtest results (ABTR) in neuropathy patients vs. the general population, and to consider the costs of screening neuropathy patients.
Methods

Subject selection
This retrospective study was approved by the Massachusetts General Hospital (MGH) institutional review board, which waived need for consent. The sample comprised all patients with objective confirmation of SFPN at MGH during 2013. Patients were not required to have had a clinical evaluation by MGH neurologists or physicians. MGH is a major referral center for peripheral nerve tests, drawing patients from throughout the northeastern US and some from across the US and other countries. Inclusion required confirmation of SFPN by any among the widely recommended objective tests-PGP9.5-immunolabeled distal-leg skin biopsy, AFT, or nerve biopsy [12, 13] -plus at least one available blood-test result. MGH performs these tests on patients referred by physicians from any office or hospital using clinically accredited facilities and approved methods and interpretations.
Data collection
Literature searches were performed to identify all neuropathy-associated medical conditions usually identified by blood tests (Table 1 ). This yielded the 21 blood tests studied here. The medical records of all eligible subjects were reviewed to extract the results of all tests that had been performed within 1 year before or after the objective test that diagnosed SFPN. Official reports of external tests were included, but secondary mentions in the record were excluded because they are potentially inaccurate. If the same blood test had been repeated, the result from closest to the date of the SFPN diagnostic test was used for the analysis. Test results were extracted into a spreadsheet, and the accuracy of data entry was confirmed. The dichotomization of test results as normal or abnormal (Table 2 ) was based on each laboratory's reference range plus the significance of values outside the reference range for neuropathy; for instance, high B12 is not associated with neuropathy, so it was coded as ''normal'' for this analysis. Three diabetes-related tests were studied; hemoglobin A1C (A1C), fasting plasma glucose (FPG), and the 2-h glucose value from 75-g oral glucose tolerance testing (OGTT). Normality was interpreted according to American Diabetes Association (ADA) standards. Diabetes was defined by A1C C6.5 %, fasting glucose C126 mg/dl or 2-h OGGT value C200 mg/dl. Prediabetes was defined by A1C C5.7 and \6.5 %, fasting glucose 100-126 mg/dl, or 2-h OGTT 140-199 mg/dl. Lyme disease diagnosis required immunoblot confirmation. The presence or absence of the following SFPN-associated symptoms was extracted from medical histories: Chronic widespread pain (using the standard definition of at least 3 months of axial, plus left and right sides, plus upper and lower body pains) [44] , chronic headache [15] , and other somatosensory symptoms (paresthesias and hypoesthesia). The cardiovascular symptoms encoded were otherwise-unexplained dizziness, POTS, and orthostatic hypotension. Gastrointestinal symptoms comprised otherwise-unexplained chronic nausea, vomiting, diarrhea, or constipation. Otherwise-unexplained urological, sexual, and sweating complaints were also encoded. All primary results of nerve conduction and electromyography studies were recorded. In the US, test costs vary between payers, so we estimated blood-test costs using the most common metric, the Medicare reimbursement rate, which was obtained from MGH's Medicare fee schedule.
Statistical analyses
Analyses were conducted using SPSS version 19. Group characteristics were represented by means ± standard deviations. Relationships between age (dichotomized by median) and gender and the prevalence of each ABTR were analyzed by Fisher's exact tests. The prevalence of each ABTR in the study sample was calculated and compared to the prevalence of each ABTR with the best available population data from epidemiologic surveys; ideally the National Health and Nutrition Examination Survey (NHANES) or the Women's Health Study (WHS). If US population data were not available, prevalences from similar countries were used as the comparator. Because the comparator data were not prospectively obtained, we did not calculate odds ratios, and we applied a very conservative arbitrary threshold to evaluate whether a particular ABTR might be specifically associated with iiSFPN. The prevalence of an ABTR in the iiSFPN cohort had to be C 300 % of the prevalence in the best available population prevalence for us to label the medical condition tested for as potentially associated with SFPN. The cost of screening to identify one abnormal blood-test result was calculated as 100/(ABTR % 9 unit test cost). Since not all patients underwent all studied tests, this estimates the minimum cost of identifying one ABTR.
Results
Sample characteristics
Two hundred thirteen patients had objective confirmation of SFPN; 166 by skin biopsy (including all 6 with nerve biopsies diagnostic for SFPN), and 47 by AFT alone. Among them, 92 % (195) had one or more blood-test results available and thus were included in the study. Only 2.5 % had known current or prior diabetes, confirming that this was a valid sample of iiSFPN patients. Patients had been referred by 29 community and hospital-based physicians of various medical specialties. Their mean age was 43.0 ± 18.6 years (range 8-81 years), 70.3 % were female, and 94.9 % were Caucasian. Among the 41 In the ''Test'' column, ''high'' indicates that only values above the reference range were labeled as abnormal and ''low'' indicates that only values below the reference range were labeled as abnormal Green shading indicates tests in which the prevalence of an ABTR in the iiSFPN cohort was C 300% than the population prevalence, thus meeting this study's criteria for excess prevalence and an association; yellow shading indicates tests in which the comparison yielded uncertain results because the prevalence of ABTR in the iiSFPN cohort was greater than the population prevalence by\300%, red shading indicates tests in which an ABTR was more common in the population than in the iiSFPN cohort, and no shading indicates that this analysis was not conducted because of missing population data, small sample size, or no positive predictive value of the abnormal test result (for ACE)
A1C hemoglobin A1C, ACE angiotensin converting enzyme, ANA antinuclear antibodies, ALT alanine transaminase, AST aspartate aminotransferase, CRP C-reactive protein, ESR erythrocyte sedimentation rate, OGTT 2 h oral glucose tolerance test, IFIX immunofixation, SPEP serum protein electrophoresis, IgA antiTTG immunoglobulin A antibodies to tissue transglutaminase J Neurol (2016) 263:2515-2527 2521 available results of EMG/NCS, 27 % identified concomitant large-fiber polyneuropathy. Regarding somatic symptoms, 86 % of the patients had chronic widespread pain and 87 % had other sensory symptoms. Regarding the studied symptoms of dysautonomia, 87 % had cardiovascular complaints, 72 % had chronic headache, 66 % had gastrointestinal symptoms, 47 % reported altered sweating, and 42 % had urological complaints.
Prevalence of abnormal blood-test results (ABTR)
Overall, 71 % of patients had C1 ABTR. The most common were high ACE in 44.6 %, high ESR in 28.0 %, and ANA C1:160 in 27.5 %. As shown in Table 2 , the prevalence of abnormal test results diagnostic for diabetes ranged between 0.0 and 5.5 % for the three different blood tests analyzed. For prediabetes, between 15.0 and 25.0 % of patients had abnormalities on the tests used to identify this. Among patients with levels of complement C3 and C4, 18 had only low C4, 12 had only low C3, and both levels were low in 6. The only sex-related association was that hypertriglyceridemia was more prevalent in males (p = 0.026). Abnormal test results for creatinine (p = 0.046) and ESR (p = 0.029) were more common in older (above median age) than younger subjects. There were too few non-Caucasians to detect race effects. Table 2 summarizes the best available data about population prevalence of each ABTR. Abnormal results of all six tests for diabetes and prediabetes were less prevalent in the iiSFPN cohort than in the NHANES-surveyed US population, which reported 5.8 % prevalence of undiagnosed diabetes and 44.9 % total prevalence of prediabetes among US adults age 45-64 [45] . Occult diabetes and prediabetes were therefore far less common among studied iiSFPN patients than in the population. In contrast, none among the eight blood-test markers of autoimmunity, immune dysregulation, and inflammation (high ESR, ANA C1:160, C-reactive protein, low C3, low C4, presence of anti-Ro/SS-A, anti-La/SS-B, IgA-anti-TTG) had ABTR prevalences below comparator population prevalences ( Table 2 ). The prevalences of high ESR, high ANA, and autoantibodies diagnostic of Sjögren's and celiac were at least 300 % of comparator population prevalences, meeting this study's definition of a potentially significant association. The cohort's 27.5 % prevalence of ANA C1:160 exceeds the comparator 8.9 % Brazilian population prevalence of ANA C1:160 [46] as well as the 13.8 % US population prevalence for titer C1:80 [47] . The excess prevalences of both low and high TSH suggest associations not only with hypothyroidism but also with thyroiditis, which is often autoimmune [48] . Together, these findings suggest that occult dysimmune/inflammatory conditions may contribute to iiSFPN in this environment.
Specificity of abnormal blood-test results
Since we did not find the population prevalence of high ACE, the specificity of the 45 % measured prevalence of high ACE was evaluated by investigating how many patients with high ACE actually had sarcoidosis. Twenty nine iiSFPN patients with high ACE had been further specifically evaluated for sarcoidosis, with chest CT performed in 7. None among the 29 was found to have sarcoidosis, so high ACE had zero positive predictive value or evidence of specificity in the current context.
Cost effectiveness of abnormal blood-test results
As shown in Table 3 , the Medicare reimbursement for each blood test ranged from $3.69 for ESR to $24.46 for Sjög-ren's autoantibodies. The total per-patient reimbursement for all tests was $290.63. The reimbursement for each individual test varied by less than 10-fold. But when the frequency of ABTR was factored in the cost of screening enough patients to obtain one abnormal test result ranged between $13.17 for ESR to $1441.82 for hepatitis C, a 100-fold difference.
Discussion
This study evaluated the sensitivity and cost of recommended screening tests for occult causes of iiSFPN in the northeastern US. It also considered the possibility that individual medical conditions tested for might be specifically associated with iiSFPN. This is the largest sample of patients with small-fiber axonopathy (Table 1) and one of the first to consider the costs of these blood tests. It has the limitations of retrospective studies including incomplete data. The fact that this was a single-center study conveys risk of referral bias. To reduce this, patients were not required to have been evaluated by any MGH physician, and the sample comprised patients referred for neuropathy testing by 29 physicians from diverse specialties practicing in the community and at other hospitals as well as at MGH. We also reduced referral bias by including patients who had undergone all available recommended diagnostic tests for SFPN rather than just one test. One limitation is that the demographics of the study sample did not precisely match the demographics of comparator epidemiologic surveys, meaning that the analyses about the specificity of these ABTR are imprecise. This is unavoidable in studies that use population-based controls, but the other option, casecontrol studies, can also be inaccurate due to much smaller samples. To compensate for this uncertainty, we used a very conservative approach of only reporting medical conditions tested for as potentially associated with iiSFPN when prevalences of ABTR were at least three times higher in the iiSFPN cohort than in the reference population. Such large differences are unlikely to be caused merely by mismatches between the iiSFPN sample and population controls. To further compensate for potential referral bias, we also included in our specificity considerations the prevalences of individual ABTRs reported from all other available studies, as discussed below. When multiple independent investigators all reported similar ABTR prevalences, and when these all aligned either below or above population prevalences, it added weight to our impressions about possible occult medical contributors to iiSFPN. In so far as we know, this is the first such study to factor results from other cohorts into its conclusions. Another limitation is that MGH's electronic record only rarely specified if glucose measurements were 2-h values from OGTT. Since we could definitively identify only eight 2-h values, we did not include 2-h values in the specificity analyses. In addition, no population data were identified with which to evaluate specificity of the sample's prevalences of high creatinine or Lyme seropositivity. Despite the fact that diabetes is the largest cause of SFPN in the US and in most other developed countries, the contribution of occult diabetes and prediabetes to iiSFPN remains uncertain. The 2011-2012 NHANES data indicate that the US prevalence of diabetes in adults between 45 and 65 years was 17.5 %, of which 5.8 % was undiagnosed/ occult [45] . In contrast, the MGH iiSFPN cohort had a smaller 5.5 % prevalence of diabetes by A1c (Table 2 ) of which 2.5 % was known. Two other idiopathic neuropathy cohorts had higher rates of undiagnosed diabetes, e.g., 13 % in Utah [28] and 9.2 % in New York [5] , but two others were similar, 1.7 % in Michigan [9] , and 3 % in New York [49] , so the overall importance of undiagnosed diabetes as a contributor to initially idiopathic SFPN remains uncertain. These prevalence differences might reflect local or demographic differences or different care patterns, so decisions on whether and how to test for undiagnosed diabetes should be made locally.
The evidence is stronger that occult prediabetes is not overrepresented among patients with initially idiopathic sensory neuropathies [50, 51] . Its prevalence here (14.7 %) and in all other US neuropathy cohorts (6.1 and 22.7 % in Michigan [6, 9] , 11 % in Ohio [52] , 7 and 11 % in New York [5, 49] ) are far below the NHANES-based US population prevalences (e.g., 44.9 % for adults aged 45-65) [45] . A prospective Minnesota study that found no increased risk for sensory polyneuropathy among prediabetic patients versus healthy controls also supports the lack of an association [53] . The situation appears similar for hypertriglyceridemia. Although it increases the risk of diabetics developing polyneuropathy [54] , prevalences in iiSFPN cohorts (24 % here, 34 % in Ohio [55] ) do not exceed the 33 % population prevalence [56] .
Autoimmune neuropathies are divided into those associated with systemic or multi-organ autoimmunity, and nervespecific conditions. Systemic lupus erythematosus [36] , Sjögren's [35, 57] , and celiac [37-39, 58, 59 ] are systemic or multi-organ autoimmune conditions that are thought to include SFPN, although odds ratios have not been determined. Serologic markers for all three conditions were far more often abnormal in the MGH cohort than in the population (Table 2) , further evidence linking these conditions to SFPN and suggesting that some cases of iiSFPN are immune mediated. The current study reported the highest prevalence of ANA C1:160 (27.5 %), with other surveys reporting 11 % [55], 12.6 % [6] , and 3 % [28] . Similarly, the 9.8 % prevalence of SS autoantibodies here exceeds the 1.8 % reported from New York [5] and the 7.5 % prevalence of SS (test unspecified) from Milan [11] . The high prevalences at MGH presumably reflect this cohort's relative youth and female predominance as compared to other neuropathy cohorts. Of note, fewer than half of patients with SS-associated painful neuropathy are SS seropositive [57] , thus the actual prevalence of Sjögren's syndrome is even higher. However, the 28 % prevalence of high ESR here is comparable to the 22.3 % prevalence identified in an older, male-predominant Michigan cohort [6] .
There are well-known large-fiber-specific autoimmune neuropathies affecting myelinating Schwann cells or nodes of Ranvier including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor mononeuropathy. Autoimmune small-fiber-predominant ganglionopathies/neuronopathies are also recognized, particularly in patients with SS or cancer [60] . It is logical that small-fiber-predominant autoimmune axonopathies should also exist, and we and others have reported cases, although these conditions are not yet wellcharacterized [15, [61] [62] [63] . Dysimmunity may be a more common cause of neuropathy in children and young adults, since they lack most other risks [15, 62] . The slightly elevated prevalence of complement consumption seen here might signal involvement of autoantibodies, which contribute to other neuropathies in young cohorts. Other surveys did not measure complement (Table 1 ), but our group reported complement consumption among young patients with iiSFPN [15] .
There is an established association between monoclonal gammopathies and large-fiber demyelinating polyneuropathy, but the question of an association with SFPN has not yet been examined. The 3.9 % sample prevalence of monoclonal gammopathy here and rates from most other US neuropathy studies (3.0 % in Utah [28] , 4.0 % in Michigan [6] , and 7.0 % in New York [5] ) are slightly higher than the 3.2 % prevalence of MGUS in US adults over age 50, even though they include patients under 50 [64] . Although inconclusive, this comparison suggests a potential association. The same situation applies to elevated liver enzymes, a marker for alcoholism and hepatitis.
Regarding nutritional contributors, folate deficiency usually produces large-fiber-predominant non-demyelinating sensory axonopathy [27] and folate levels do not correlate with risk of POTS, which is a common symptom of SFPN [65] . Given the lack of evidence for an association here, plus the rarity of folate deficiency in other US neuropathy cohorts (0 %) [28] and the resulting high cost of screening (Table 2) , it may not be cost-effective to screen for folate deficiency in iiSFPN in the northeastern US (Table 2) . When vitamin B12 is considered, the 1.5 % prevalence of B12 deficiency here, and the 1.4 % prevalence in another New York study [5] and 2 % prevalence in Utah [28] are below population prevalence. We identified only one exception, the 6 % prevalence reported from one New York study [49] . Both low and high TSH were overrepresented in the MGH study sample by an order of magnitude as compared to population prevalence. The American Academy of Neurology and other groups do not recommend screening neuropathy patients for hypothyroidism [6, 8] , but the elevated prevalence of abnormal test results in multiple studies, the intermediate cost of TSH screening, and the immediate actionability of abnormal results, suggest that TSH be considered for inclusion in screening recommendations for the US.
We also analyzed the costs of screening (Table 3) . Medicare reimbursement for the three tests recommended by the AAN [8] (glucose, B12, and SPEP/IFIX) was $42.97/ person, and C6.8 % of the MGH cohort would have at least one ABTR. The Utah group recommended screening panel (OGTT, B12, SPEP/IFIX, and ANA) [28] incurred Medicare costs of $59.46 per patient with C28.6 % probability of C1 abnormal result in the MGH cohort. In contrast, reimbursement for the two most cost-effective and specifically SFPNassociated blood tests from the current analysis-ESR and ANA-was only $20.18/person, and these two tests alone would convey a higher 38.5 % probability of detecting at least one abnormal test result in the MGH cohort, improving sensitivity plus reducing per-patient cost. Reimbursement for the three most cost-effective and specifically associated blood tests from the current analysis-ESR, ANA, and C3-was $36.56/person with 41.0 % probability of detecting one ABTR in MGH cohort. Reimbursement for the six most costeffective and specifically associated blood tests from the current analysis-ESR, ANA, C3, Sjögren's autoantibodies, celiac testing (IgA-anti-TTG), and TSH-was $99.57/person with 45.6 % probability of detecting one ABTR in the MGH cohort.
Another consideration pertinent to cost effectiveness is the ''actionability'' of each ABTR [9] . Some tests, e.g., for diabetes, malnutrition, or infectious diseases are highly actionable since they reliably diagnose curable medical conditions. The actionability of dysimmune/inflammatory markers varies. The IgA anti-TTG test for celiac has [95 % sensitivity and specificity for detecting celiac, even for the many patients with ''silent celiac'' who lack gastrointestinal symptoms [66] , and gluten-free diets reduce celiac-induced damage and symptoms. Thus, celiac tests may be more useful than the cheaper but less-actionable ANA and ESR. However, persistently elevated ANA or ESR typically prompt additional evaluation that can uncover treatable diagnoses, including systemic lupus erythematosus. And new treatments, e.g., for hepatitis C, add new rationale for screening. In accountable-care models, it may be most cost-effective to sequentially screen iiSFPN patients beginning with high yield, specific, low cost, actionable tests and performing others later only if needed. Testing decisions should also be personalized, since risks vary with patients' locations, demographic, personal, and family histories. Familial amyloid polyneuropathy is more prevalent in specific European regions for instance. Table 1 reveals that no prior studies reported the prevalences of abnormal results for every test they studied. Most did not include their study's definitions of normal and abnormal results for each test. More comprehensive reporting in future studies is encouraged to enable systematic review and pooling of results from multiple studies. This add power and can inform about even rare causes of initially idiopathic polyneuropathy.
